RhIG for the treatment of immune thrombocytopenia: Consensus and controversy (CME)

Transfusion

Volumn 52, Issue 5, 2012, Pages 1126-1136

  Despotovic, Jenny M ^{a,b,c,d,e,f,g,h}   Lambert, Michele P ^{a,b,c,d,e,f,g,h}   Herman, Jay H ^{a,b,c,d,e,f,g,h}   Gernsheimer, Terry B ^{a,b,c,d,e,f,g,h}   McCrae, Keith R ^{a,b,c,d,e,f,g,h}   Tarantino, Michael D ^{a,b,c,d,e,f,g,h}   Bussel, James B ^{a,b,c,d,e,f,g,h}  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g Bleeding and Clotting Disorders Institute   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY;

CONSENSUS DEVELOPMENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRAVASCULAR HEMOLYSIS; KIDNEY FAILURE; PATIENT SELECTION; RARE DISEASE; REVIEW; RISK ASSESSMENT;

HEMOLYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RHO(D) IMMUNE GLOBULIN;

EID: 84861083164     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03384.x     Document Type: Review

References (66)

1. Cines DB, Blanchette VS,. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
2. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ,. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40.
3. Rank A, Weigert O, Ostermann H,. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics 2010; 4: 139-45.
4. Semple JW, Provan D, Garvey MB, Freedman J,. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 2010; 17: 590-5.
5. Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J,. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87: 4245-54.
6. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H,. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-4.
7. Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M,. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008; 93: 1428-30.
8. Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, Shiraga M, Honda S, Kanakura Y, Matsuzawa Y,. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-6.
9. Nagasawa T, Hasegawa Y, Shimizu S, Kawashima Y, Nishimura S, Suzukawa K, Mukai H, Hori M, Komeno T, Kojima H, Ninomiya H, Tahara T, Abe T,. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br J Haematol 1998; 101: 242-4.
10. Nugent D, McMillan R, Nichol JL, Slichter SJ,. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585-96.
11. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL,. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83: 150-4.
12. El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS,. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol 2006; 115: 46-52.
13. Moser AM, Shalev H, Kapelushnik J,. Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2002; 19: 407-11.
14. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB,. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89: 2689-700.
15. Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, Weber LC, Davis ML, Lynn H, Nugent DJ,. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006; 148: 489-94.
16. Son DW, Jeon IS, Yang SW, Cho SH,. A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children. J Pediatr Hematol Oncol 2008; 30: 598-601.
17. Cooper N, Heddle NM, Haas M, Reid ME, Lesser ML, Fleit HB, Woloski BM, Bussel JB,. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004; 124: 511-8.
18. Ware RE, Zimmerman SA,. Anti-D: mechanisms of action. Semin Hematol 1998; 35 (Suppl 1): 14-22.
19. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB,. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112: 1076-8.
20. Gaines AR,. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000; 95: 2523-9.
21. Gaines AR,. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106: 1532-7.
22. Food and Drug Administration. US FDA black-box warning. 2011. [cited 2011 Sep 16]. Available from: URL http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm203739.htm
23. US Department of Health and Human Services Food and Drug Administration. Good pharmacovigilance practices and pharmacoepidemiologic assessment. Guid Ind 2005; 4: 9-10.
24. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP,. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
25. Bussel JB, Hilgartner MW,. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol 1984; 56: 1-7.
26. Imbach P, Barandun S, Hirt A, Wagner HP,. Intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) in childhood. Am J Pediatr Hematol Oncol 1984; 6: 171-4.
27. Lusher JM, Warrier I,. Use of intravenous gamma globulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 1987; 83: 10-6.
28. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, Rieben R,. Intravenous immunoglobulins-understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl 1): 2-13.
29. Salama A, Mueller-Eckhardt C, Kiefel V,. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2: 193-5.
30. Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C,. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)). Blut 1984; 49: 29-35.
31. Hoppe HH, Mester T, Hennig W, Krebs HJ,. Prevention of Rh-immunization. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography (IEC). Vox Sang 1973; 25: 308-16.
32. Bowman JM, Friesen AD, Pollock JM, Taylor WE,. WinRho: Rh immune globulin prepared by ion exchange for intravenous use. Can Med Assoc J 1980; 123: 1121-7.
33. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM,. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77: 1884-93.
34. Semple JW, Allen D, Rutherford M, Woloski M, David M, Wakefield C, Butchart S, Freedman J, Blanchette V,. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol 2002; 69: 225-7.
35. Crow AR, Lazarus AH,. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 2008; 22: 103-16.
36. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ,. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86.
37. Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld EJ, Vesely SK, Adix L, Blanchette VS, Kuhne T,. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112: 4003-8.
38. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB,. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009; 114: 4777-83.
39. Cooper N, Tarantino M,. Safety of alternative treatments of ITP: a meta-analysis. International Society of Thrombosis and Haemostasis 2009 Meeting. 2009.
40. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M,. Safety profile of WinRho anti-D. Semin Hematol 1998; 35 (Suppl 1): 9-13.
41. Hidalgo C, Romano EL, Linares J, Suarez G,. Complement fixation by Rh blood group antibodies. Transfusion 1979; 19: 250-4.
42. Suyama K, Goldstein J,. Enzymatic evidence for differences in the placement of Rh antigens within the red cell membrane. Blood 1990; 75: 255-60.
43. Romano EL, Stolinski C, Hughes-Jones NC,. Distribution and mobility of the A, D and c antigens on human red cell membranes: studies with a gold-labelled antiglobulin reagent. Br J Haematol 1975; 30: 507-16.
44. Gaines AR, Lee-Stroka H, Byrne K, Scott DE, Uhl L, Lazarus E, Stroncek DF,. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. Transfusion 2009; 49: 1050-8.
45. Garratty G,. What is the mechanism for acute hemolysis occurring in some patients after intravenous anti-D therapy for immune thrombocytopenic purpura? Transfusion 2009; 49: 1026-31.
46. Borenstain-Ben YV, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A,. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993; 44: 63-5.
47. Chun NS, Savani B, Seder RH, Taplin ME,. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Am J Hematol 2003; 74: 276-9.
48. Cheung E, Liebman HA,. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009; 3: 57-62.
49. Kees-Folts D, Abt AB, Domen RE, Freiberg AS,. Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Pediatr Nephrol 2002; 17: 91-6.
50. Levendoglu-Tugal O, Jayabose S,. Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia. J Pediatr Hematol Oncol 2001; 23: 460-3.
51. Olofinboba KA, Greenberg BR,. Successful treatment of infectious mononucleosis-associated immune thrombocytopenia with WinRho anti-D immunoglobulin complicated by severe hemolysis. Am J Hematol 2000; 65: 178.
52. Berger-Achituv S, Ellis MH, Curtis BR, Wolach B,. Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent. Am J Hematol 2008; 83: 676-8.
53. Tarantino MD, Bussel JB, Cines DB, McCrae KR, Gernsheimer T, Liebman HA, Wong WY, Kulkarni R, Grabowski E, McMillan R,. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood 2007; 109: 5527.
54. Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA,. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4: 1993-7.
55. Gordon DJ, Sloan SR, de Jong JL,. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. Am J Hematol 2009; 84: 771-2.
56. Welles CC, Tambra S, Lafayette RA,. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55: 148-51.
57. Daw Z, Padmore R, Neurath D, Cober N, Tokessy M, Desjardins D, Olberg B, Tinmouth A, Giulivi A,. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48: 1598-601.
58. Wilson JR, Bhoopalam H, Fisher M,. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve 1997; 20: 1142-5.
59. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM,. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120: 926-8.
60. Nakagawa M, Watanabe N, Okuno M, Kondo M, Okagawa H, Taga T,. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. Am J Hematol 2000; 63: 160-1.
61. Caress JB, Kennedy BL, Eickman KD,. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010; 9: 971-9.
62. Itkin YM, Trujillo TC,. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy 2005; 25: 886-92.
63. Renal insufficiency and failure associated with immune globulin intravenous therapy-United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48: 518-21.
64. Tankerslay D, Preston M, Finlayson J,. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988; 25: 41-8.
65. Knezevic-Maramica I, Kruskall MS,. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460-80.
66. Rizk A, Gorson KC, Kenney L, Weinstein R,. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001; 41: 264-8.